Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 82 articles:
HTML format
Text format



Single Articles


    April 2018
  1. SHIH TC, Liu R, Wu CT, Li X, et al
    Targeting Galectin-1 impairs castration-resistant prostate cancer progression and invasion.
    Clin Cancer Res. 2018 Apr 17. pii: 1078-0432.CCR-18-0157.
    PubMed     Text format     Abstract available


  2. GORDEVICIUS J, Krisciunas A, Groot DE, Yip SM, et al
    Cell-free DNA modification dynamics in abiraterone acetate-treated prostate cancer patients.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0101.
    PubMed     Text format     Abstract available


    March 2018
  3. SCROGGINS B, Matsuo M, White A, Saito K, et al
    Hyperpolarized [1-(13)C]-pyruvate magnetic resonance spectroscopic imaging of prostate cancer in vivo predicts efficacy of targeting the Warburg effect.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1957.
    PubMed     Text format     Abstract available


  4. WELTI J, Sharp A, Yuan W, Dolling DI, et al
    Targeting bromodomain and extra-terminal (BET) family proteins in castration resistant prostate cancer (CRPC).
    Clin Cancer Res. 2018 Mar 19. pii: 1078-0432.CCR-17-3571.
    PubMed     Text format     Abstract available


    February 2018
  5. MARANTO C, Udhane V, Hoang DT, Gu L, et al
    STAT5A/B BLOCKADE SENSITIZES PROSTATE CANCER TO RADIATION THROUGH INHIBITION OF RAD51 AND DNA REPAIR.
    Clin Cancer Res. 2018 Feb 26. pii: 1078-0432.CCR-17-2768.
    PubMed     Text format     Abstract available


  6. HECK MM, Retz M, Bandur M, Souchay M, et al
    Molecular lymph node status for prognostic stratification of prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-3771.
    PubMed     Text format     Abstract available


  7. KIM K, Watson PA, Lebdai S, Jebiwott S, et al
    Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-3474.
    PubMed     Text format     Abstract available


    November 2017
  8. WANG C, Peng G, Huang H, Liu F, et al
    Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-2446.
    PubMed     Text format     Abstract available


  9. YANG Y, Bai Y, He Y, Zhao Y, et al
    PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer.
    Clin Cancer Res. 2017 Nov 22. pii: clincanres.2006.2017.
    PubMed     Text format     Abstract available


  10. PUHR M, Hoefer J, Eigentler A, Ploner C, et al
    The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved anti-androgen therapy.
    Clin Cancer Res. 2017 Nov 20. pii: clincanres.0989.2017.
    PubMed     Text format     Abstract available


  11. BELDERBOS BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, et al
    Influence of Enzalutamide on Cabazitaxel Pharmacokinetics; a Drug-Drug Interaction Study in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients.
    Clin Cancer Res. 2017 Nov 17. pii: clincanres.2336.2017.
    PubMed     Text format     Abstract available


  12. ZHANG W, Liu B, Wu W, Li L, et al
    Targeting the MYCN-PARP-DNA Damage Response Pathway inNeuroendocrine Prostate Cancer.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.1872.2017.
    PubMed     Text format     Abstract available


  13. PALLER CJ, Zhou XC, Heath EI, Taplin ME, et al
    Muscadine Grape Skin Extract in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.
    Clin Cancer Res. 2017 Nov 7. pii: clincanres.1100.2017.
    PubMed     Text format     Abstract available


    September 2017
  14. KALINA JL, Neilson DS, Lin YY, Hamilton PT, et al
    Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T cell Epitopes & Immune Signatures in a Subset of Prostate Cancer.
    Clin Cancer Res. 2017 Sep 27. pii: clincanres.0618.2017.
    PubMed     Text format     Abstract available


  15. LABBE DP, Sweeney CJ, Brown M, Galbo P, et al
    TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0413.2017.
    PubMed     Text format     Abstract available


  16. KETOLA K, Munuganti RS, Davies A, Nip KM, et al
    Targeting Prostate Cancer Subtype 1 by Forkhead box M1 Pathway Inhibition.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0901.2017.
    PubMed     Text format     Abstract available


  17. CALAGUA C, Russo J, Sun Y, Schaefer R, et al
    Expression of PD-L1 in Hormone-naive and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
    Clin Cancer Res. 2017 Sep 11. pii: clincanres.0807.2017.
    PubMed     Text format     Abstract available


    August 2017
  18. BELTRAN H, Wyatt AW, Chedgy E, Donoghue A, et al
    Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Clin Cancer Res. 2017 Aug 25. pii: clincanres.1034.2017.
    PubMed     Text format     Abstract available


  19. GUEDES L, Antonarakis ES, Schweizer MT, Mirkheshti N, et al
    MSH2 Loss in Primary Prostate Cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0955.2017.
    PubMed     Text format     Abstract available


    July 2017
  20. GAO WQ, Guo Y, Zhang K, Cheng C, et al
    Numb-/low enriches a castration resistant prostate cancer cell subpopulation associated with enhanced Notch and Hedgehog signaling.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0913.2017.
    PubMed     Text format     Abstract available


  21. SEED G, Yuan W, Mateo J, Carreira S, et al
    Gene Copy Number Estimation From Targeted Next Generation Sequencing Of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0972.2017.
    PubMed     Text format     Abstract available



  22. Retraction: GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.
    Clin Cancer Res. 2017;23:3973.
    PubMed     Text format    



  23. Correction: A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2017;23:3970.
    PubMed     Text format    


    June 2017
  24. BILUSIC M, Madan RA, Gulley JL
    Immunotherapy of Prostate Cancer: Facts and Hopes.
    Clin Cancer Res. 2017 Jun 29. pii: clincanres.0019.2017.
    PubMed     Text format     Abstract available


  25. XU L, Mao X, Guo T, Chan PY, et al
    The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis.
    Clin Cancer Res. 2017 Jun 14. pii: clincanres.3081.2016.
    PubMed     Text format     Abstract available


    May 2017
  26. BAN K, Feng S, Shao L, Ittmann M, et al
    RET signaling in prostate cancer.
    Clin Cancer Res. 2017 May 10. pii: clincanres.0528.2017.
    PubMed     Text format     Abstract available


  27. KOHLI M, Ho Y, Hillman DW, Van Etten JL, et al
    Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.
    Clin Cancer Res. 2017 May 4. pii: clincanres.0017.2017.
    PubMed     Text format     Abstract available


  28. MONTGOMERY B, Tretiakova MS, Joshua AM, Gleave ME, et al
    Neoadjuvant Enzalutamide Prior to Prostatectomy.
    Clin Cancer Res. 2017;23:2169-2176.
    PubMed     Text format     Abstract available


    April 2017
  29. GUEDES L, Almutairi F, Haffner MC, Rajoria G, et al
    Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.0257.2017.
    PubMed     Text format     Abstract available


  30. MOSTAGHEL EA, Cho E, Zhang A, Alyamani M, et al
    Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.
    Clin Cancer Res. 2017 Apr 7. pii: clincanres.2245.2016.
    PubMed     Text format     Abstract available


  31. NIEUWEBOER AJ, de Graan AM, Hamberg P, Bins S, et al
    Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.
    Clin Cancer Res. 2017;23:1679-1683.
    PubMed     Text format     Abstract available


  32. NESBITT H, Byrne NM, Williams SN, Ming L, et al
    Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
    Clin Cancer Res. 2017;23:1797-1808.
    PubMed     Text format     Abstract available


    March 2017
  33. SUOMINEN MI, Fagerlund KM, Rissanen JP, Konkol YM, et al
    Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models.
    Clin Cancer Res. 2017 Mar 31. pii: clincanres.2955.2016.
    PubMed     Text format     Abstract available


    February 2017
  34. RATHKOPF DE, Antonarakis ES, Shore ND, Tutrone RF, et al
    Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
    Clin Cancer Res. 2017 Feb 17. pii: clincanres.2509.2016.
    PubMed     Text format     Abstract available


  35. SAXENA R, Yang C, Rao M, Turaga RC, et al
    Preclinical development of a non-toxic oral formulation of monoethanolamine, a lipid precursor, for prostate cancer treatment.
    Clin Cancer Res. 2017 Feb 6. pii: clincanres.1716.2016.
    PubMed     Text format     Abstract available


    January 2017
  36. WANG R, Wang J, Gao G, Hu J, et al
    Pre-biopsy mp-MRI can help to improve the predictive performance in prostate cancer: a prospective study in 1478 consecutive patients.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2884.2016.
    PubMed     Text format     Abstract available


  37. KIM K, Zhang H, LaRosa S, Jebiwott S, et al
    Bombesin Antagonist Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.
    Clin Cancer Res. 2017 Jan 20. pii: clincanres.2745.2016.
    PubMed     Text format     Abstract available


  38. CASTIELLO L, Sabatino M, Ren J, Terabe M, et al
    Expression of CD14, IL-10 and tolerogenic signature in dendritic cells inversely correlate with response to TARP vaccination in prostate cancer patients.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.2199.2016.
    PubMed     Text format     Abstract available



  39. Correction: Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2017;23:323.
    PubMed     Text format    


  40. SINNOTT JA, Peisch SF, Tyekucheva S, Gerke T, et al
    Prognostic Utility of a New mRNA Expression Signature of Gleason Score.
    Clin Cancer Res. 2017;23:81-87.
    PubMed     Text format     Abstract available


    December 2016
  41. LAM HM, McMullin R, Nguyen H, Coleman I, et al
    Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts.
    Clin Cancer Res. 2016 Dec 19. pii: clincanres.2054.2016.
    PubMed     Text format     Abstract available


    November 2016
  42. ANTONARAKIS ES, Kibel AS, Yu EY, Karsh LI, et al
    Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically-Recurrent Prostate Cancer: A Phase II Randomized Trial.
    Clin Cancer Res. 2016 Nov 10. pii: clincanres.1780.2016.
    PubMed     Text format     Abstract available


  43. YIN Y, Zhang Q, Zhang H, He Y, et al
    Molecular signature to risk-stratify prostate cancer of intermediate risk.
    Clin Cancer Res. 2016 Nov 1. pii: clincanres.2400.2016.
    PubMed     Text format     Abstract available


    October 2016
  44. PENET MF, Kakkad S, Pathak AP, Krishnamachary B, et al
    Structure and Function of a Prostate Cancer Dissemination Permissive Extracellular Matrix.
    Clin Cancer Res. 2016 Oct 31. pii: clincanres.1516.2016.
    PubMed     Text format     Abstract available


  45. SAYYID R, Evans A, Hersey K, Maloni R, et al
    A Phase II, Randomized, Open Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Clin Cancer Res. 2016 Oct 18. pii: clincanres.1790.2016.
    PubMed     Text format     Abstract available


  46. PALAPATTU GS, Salami SS, Cani AK, Hovelson DH, et al
    Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer.
    Clin Cancer Res. 2016 Oct 7. doi: 10.1158/1078-0432.CCR-16-1454.
    PubMed     Text format     Abstract available


  47. KUHN P, Carlsson A, Luttgen MS, Dizon KK, et al
    Paired high-content analysis of prostate cancer cells in bone marrow and blood characterizes increased androgen receptor expression in tumor cell clusters.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.1355.2016.
    PubMed     Text format     Abstract available


    September 2016
  48. TAPLIN ME, McKay RR, Werner L, Mostaghel EA, et al
    A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2016 Sep 28. pii: clincanres.0987.2016.
    PubMed     Text format     Abstract available


  49. BRAGELMANN J, Klumper N, Offermann A, von Massenhausen A, et al
    Pan-cancer analysis of the Mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.0094.2016.
    PubMed     Text format     Abstract available


  50. HELLER G, Fizazi K, McCormack RT, Molina A, et al
    The added value of circulating tumour cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1224.2016.
    PubMed     Text format     Abstract available


  51. LUK IS, Shrestha R, Xue H, Wang Y, et al
    BIRC6-targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.0718.2016.
    PubMed     Text format     Abstract available


  52. GUPTA S, Li J, Kemeny G, Bitting RL, et al
    Whole genomic copy number alterations in circulating tumor cells from men with abiraterone or enzalutamide resistant metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1211.2016.
    PubMed     Text format     Abstract available


    August 2016
  53. QU F, Xie W, Nakabayashi M, Zhang H, et al
    Association of AR-V7 and prostate specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.1070.2016.
    PubMed     Text format     Abstract available


  54. REBELLO RJ, Kusnadi E, Cameron DP, Pearson HB, et al
    The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer.
    Clin Cancer Res. 2016 Aug 2. pii: clincanres.0124.2016.
    PubMed     Text format     Abstract available


    July 2016
  55. SHOURIDEH M, Azabdaftari G, Attwood K, DePriest A, et al
    GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.
    Clin Cancer Res. 2016 Jul 25. pii: clincanres.0137.2016.
    PubMed     Text format     Abstract available


  56. SAYLOR PJ, Lee RJ, Arora KS, Deshpande V, et al
    Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.0237.2016.
    PubMed     Text format     Abstract available



  57. Correction: Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
    Clin Cancer Res. 2016;22:3702.
    PubMed     Text format    


    June 2016
  58. ZHAO S, Geybels MS, Leonardson A, Rubicz R, et al
    Epigenome-wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-lethal Progression in Men with Clinically Localized Prostate Cancer.
    Clin Cancer Res. 2016 Jun 29. pii: clincanres.0549.2016.
    PubMed     Text format     Abstract available


  59. SHARP A, Welti J, Blagg J, de Bono JS, et al
    Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2016 Jun 21. pii: clincanres.1137.2016.
    PubMed     Text format     Abstract available


  60. BANSAL N, Bartucci M, Yusuff S, Davis S, et al
    BMI-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer.
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.3107.2015.
    PubMed     Text format     Abstract available


  61. YAMIN G, Schenker-Ahmed NM, Shabaik A, Adams D, et al
    Voxel Level Radiologic-Pathologic Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in Prostate Cancer.
    Clin Cancer Res. 2016;22:2668-74.
    PubMed     Text format     Abstract available


    May 2016
  62. GUEDES L, Morais C, Almutairi F, Haffner MC, et al
    Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer.
    Clin Cancer Res. 2016 May 10. pii: clincanres.0205.2016.
    PubMed     Text format     Abstract available


  63. CHUA ML, Bristow RG
    Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or <I>Frenemy</I>?
    Clin Cancer Res. 2016 May 10. pii: clincanres.0381.2016.
    PubMed     Text format     Abstract available


  64. YANG YC, Banuelos CA, Mawji NR, Wang J, et al
    Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer.
    Clin Cancer Res. 2016 May 2. pii: clincanres.2901.2015.
    PubMed     Text format     Abstract available


    April 2016
  65. CHEN X, Li Q, Liu X, Liu C, et al
    Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer (CRPC).
    Clin Cancer Res. 2016 Apr 8. pii: clincanres.2956.2015.
    PubMed     Text format     Abstract available


    March 2016
  66. LOPEZ SM, Agoulnik AI, Zhang M, Peterson LE, et al
    Nuclear Receptor Corepressor 1 expression and output declines with prostate cancer progression.
    Clin Cancer Res. 2016 Mar 11. pii: clincanres.1983.2015.
    PubMed     Text format     Abstract available


  67. GAO S, Ye H, Gerrin S, Wang H, et al
    ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Clin Cancer Res. 2016 Mar 2. pii: clincanres.2309.2015.
    PubMed     Text format     Abstract available


    February 2016
  68. MORRIS MJ, Rathkopf DE, Novotny W, Gibbons JA, et al
    Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2016 Feb 8. pii: clincanres.2638.2015.
    PubMed     Text format     Abstract available


  69. HUSSAIN M, Le Moulec S, Gimmi C, Bruns R, et al
    Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-resistant Prostate Cancer.
    Clin Cancer Res. 2016 Feb 2. pii: clincanres.2512.2015.
    PubMed     Text format     Abstract available


  70. HEDAYATI M, Haffner MC, Coulter J, Raval RR, et al
    Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation.
    Clin Cancer Res. 2016 Feb 1. pii: clincanres.1147.2015.
    PubMed     Text format     Abstract available


    January 2016
  71. LENNARTZ M, Minner S, Brasch S, Wittmann H, et al
    The combination of DNA ploidy status and PTEN/6q15 deletions provides strong and independent prognostic information in prostate cancer.
    Clin Cancer Res. 2016 Jan 26. pii: clincanres.0635.2015.
    PubMed     Text format     Abstract available


  72. CHOI SY, Xue H, Wu R, Fazli L, et al
    The MCT4 Gene: a Novel, Potential Target for Therapy of Advanced Prostate Cancer.
    Clin Cancer Res. 2016 Jan 11. pii: clincanres.1624.2015.
    PubMed     Text format     Abstract available



  73. Retraction: Suppression of N-Methyl-N-nitrosourea/Testosterone-Induced Rat Prostate Cancer Growth by Celecoxib: Effects on Cyclooxygenase-2, Cell Cycle Regulation, and Apoptosis Mechanism(s).
    Clin Cancer Res. 2016;22:270.
    PubMed     Text format    


  74. HABERKORN U, Eder M, Kopka K, Babich JW, et al
    New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
    Clin Cancer Res. 2016;22:9-15.
    PubMed     Text format     Abstract available


    December 2015
  75. ZHANG W, Yi B, Wang C, Chen D, et al
    Silencing of CD24 enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cells.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.1927.2015.
    PubMed     Text format     Abstract available


  76. VAN LEEUWEN FW, van der Poel HG
    Surgical Guidance in Prostate Cancer: "From Molecule to Man" Translations.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.2575.2015.
    PubMed     Text format     Abstract available


  77. KATO M, Banuelos CA, Imamura Y, Leung JK, et al
    Co-targeting Androgen Receptor Splice Variants and mTOR signaling pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.2119.2015.
    PubMed     Text format     Abstract available


  78. BELTRAN H, Jendrisak A, Landers M, Mosquera JM, et al
    The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.
    Clin Cancer Res. 2015 Dec 15. pii: clincanres.0137.2015.
    PubMed     Text format     Abstract available


  79. ZHAO SG, Evans JR, Kothari V, Sun G, et al
    The landscape of prognostic outlier genes in high-risk prostate cancer.
    Clin Cancer Res. 2015 Dec 2. pii: clincanres.1250.2015.
    PubMed     Text format     Abstract available


    November 2015
  80. GEVENSLEBEN H, Dietrich D, Golletz C, Steiner S, et al
    The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer.
    Clin Cancer Res. 2015 Nov 16. pii: clincanres.2042.2015.
    PubMed     Text format     Abstract available


  81. MEHRA N, Zafeiriou Z, Lorente D, Terstappen LW, et al
    CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer.
    Clin Cancer Res. 2015;21:4992-5.
    PubMed     Text format     Abstract available


    March 2015
  82. SHARIFI N
    Steroid sidestep: evading androgen ablation by abiraterone.
    Clin Cancer Res. 2015;21:1240-2.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: